Researchers pan pharma DTC advertising for high spending on low-value drugs — JAMA report
New research is looking to connect the dots between direct-to-consumer (DTC) advertising and lower clinical benefits or therapeutic value. A study published on Tuesday in JAMA found that among the group of top-selling drugs in 2020, brands that had a lower added benefit spent more on DTC advertising.
The researchers from the Johns Hopkins Bloomberg School of Public Health broke out 12 of the top spenders and ranked them by the highest share of promotional spending that went to DTC ads. Included in the group were Yervoy (97.6% share on DTC), Ocrevus (97.4%), Ibrance (95.8%) and Opdivo (92.2%).
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.